Browse > Article

Clinical Study of Topotecan as Second-Line Treatment in Small Cell Lung Cancer  

Kim, Hak-Ryul (Department of Internal Medicine, Wonkwang University, School of Medicine)
Yang, Sei-Hoon (Department of Internal Medicine, Wonkwang University, School of Medicine)
Jeong, Eun-Taik (Department of Internal Medicine, Wonkwang University, School of Medicine)
Publication Information
Tuberculosis and Respiratory Diseases / v.52, no.3, 2002 , pp. 230-240 More about this Journal
Abstract
Background : The majority of chemotherapy-treated small cell lung cancers(SCLC) patients eventually recur. Although many patients are in excellent physical condition at the time of recurrence, few drugs or drug combinations are capable of effecting a tumor regression in this setting. Topotecan, a topoisomerase I inhibitor, is one of the more widely studied single afents in SCLC. The aim of this study was to determine the response rate, survival and toxicity of topotecan as a second line traeatment SCLC. Materials and Methods : 19 patients with measurable SCLC, progressive during the first line chemotherapy (9 cases) or recurrent after the first line chemotherpy(10 cases), were enrolled in this study. Topotecan was administered as a 30-minute daily infusion at a dose of 1.5mg/$m^2$ for 5 consecutive days, every 3 weeks. Results : The overall response rate was 26.3%(5/19, CR 2, PR 3, SD 3, PD 11). The median survival was 24 weeks. The response rate and survival were poor in the nonresponders during first chemotherapy, those who were refractory to the first chemotherapy(recurrent within 3 months after completion of first chemotherapy) and extensive disease, but the results were not statistically significant. The toxicities were mainly hematologic and anemia grade III 1/90, leukopenia grade III 6/90 IV 4/90, thrombocytopenia grade III 1/90 IV 1/90, vomiting grade III 1/90 of cycles were occurred. There was no treatment-related deaths due to severe myelosuppression. Conclusion : Topotecan can be an active second line chemotherapeutic agent for treating SCLC.
Keywords
Small cell lung cancer; Second line chemotherapy Topotecan;
Citations & Related Records

Times Cited By SCOPUS : 0
연도 인용수 순위
  • Reference